DCTH insider trading
NasdaqCM HealthcareDELCATH SYSTEMS, INC.: insider trade history from SEC Form 4 filings.
About DELCATH SYSTEMS, INC.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.
Company website: www.delcath.com
DCTH insider activity at a glance
FilingIQ tracks 149 insider transactions for DCTH in filings since Jun 12, 2015. The most recent transaction is dated Oct 13, 2026.
Across the full history, 85 open-market purchases
and 0 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
How FilingIQ classifies each line, and the seven facts it shows on every open-market purchase and sale, are documented on the methodology page.
Latest DCTH Form 4 filings
Most recent disclosures. Sign up to filter by transaction code, insider role or dollar value.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for DCTH?
- FilingIQ tracks 149 Form 4 insider transactions for DCTH (DELCATH SYSTEMS, INC.), covering filings from Jun 12, 2015 onwards. 2 of those are dated within the last 90 days.
- Are DCTH insiders net buyers or net sellers?
- Across the full Form 4 history for DCTH, 85 transactions (57%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DCTH insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ links every filing to the insider's SEC CIK, marks plan trades, tax withholding, option exercises, gifts, derivatives and amendments, and shows each open-market purchase and sale with the same fixed facts. It does not rate the stock.
- What sector is DCTH in?
- DELCATH SYSTEMS, INC. (DCTH) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $345.54M.
Methodology & sources
Every DCTH insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). How lines are classified and which facts FilingIQ adds is documented on the methodology page; the people behind it are on the team page. Not investment advice; see disclaimer.